For Immediate Release March 4, 2021

Montreal, Quebec, Canada — (GLOBE NEWSWIRE) — Sunshine Biopharma Inc. (OTC PINK:  “SBFM”), a pharmaceutical company focused on the research, development and  commercialization of oncology and antiviral drugs, today announced that it has received shipment  of a new batch of Adva-27a from its manufacturer in China. The material has been delivered to  the laboratories of Sunshine Biopharma’s drug development partner in Montreal (Canada). 

Following initial QA/QC testing of the material for specific biological activity, Sunshine Biopharma  will proceed to performing tumor inhibition studies on xenograft mice harboring tumors of human  pancreatic cancer origin. Pancreatic Cancer is Sunshine Biopharma’s clinical trials indication for  Adva-27a. Among several other cancer types, Pancreatic Cancer is resistant to existing 

chemotherapy drugs but has been shown to be susceptible to Adva-27a in preclinical studies. 

“We look forward to initiating the xenograft mice studies as soon as the QA/QC testing is done.  Mice studies of this sort provide crucial information and technical guidance for the clinical trials to  be conducted in subsequent drug development events,” said Dr. Steve Slilaty, CEO of Sunshine  Biopharma. 

About Sunshine Biopharma 

In addition, to working on the development of a treatment for COVID-19 which is now in the  transgenic mice testing phase, Sunshine Biopharma is engaged in the development Adva-27a, a  unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of  Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells,  Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for  Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General  Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual  property pertaining to Adva-27a. 

Safe Harbor Forward-Looking Statements 

This press release may contain forward looking statements which are based on current expectations, forecasts, and  assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially  from those anticipated or expected, including statements related to the amount and timing of expected revenues  statements related to our financial performance, expected income, distributions, and future growth for upcoming 

quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company  with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ  materially from those projected in or contemplated by the forward-looking statements due to a number of factors  detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain  growth or achieve profitability based upon many factors including but not limited to general stock market conditions.  Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC filings. We have  incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines  noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long  term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s)  based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted  at this time. 

For Additional Information Contact: 

Camille Sebaaly, CFO 

Sunshine Biopharma Inc. 

Direct Line: 514-814-0464 

[email protected]